Australia is anticipating the availability of Retatrutide, a innovative medication by Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, presents significant results in clinical trials, https://webcastlist.com/story23496616/retatrutide-australia-a-potential-advancement-for-obesity-treatment